Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Uricolytic agent
Original Date: 
August 2005
Revised Date: 
October 2018
  • Rapid treatment of acute hyperuricemia, especially in the event of impending or acute renal failure (tumor lysis syndrome)
Reconstitution and Stability: 
  • Available in vials containing 1.5 mg of rasburicase as a lyophilized powder
  • Reconstitute with 1 mL of supplied diluent (sterile water for injection with Poloxamer 188) for a final concentration of 1.5 mg/mL
  • Swirl gently to dissolve.  Do not vortex or shake vial.
  • Reconstituted solution may be diluted further with 0.9% NS to a total volume of 50 mL
  • Reconstituted or diluted solution stable 24 hours refrigerated

- Solutions Compatible: 0.9% NS

- No other compatibility information.  Run in dedicated line.  Flush well before and after with at least 15 mL of  0.9% NS


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct


IV Intermittent Infusion

YES  Large Volume Pump ONLY
Infusion time: 30 minutes
Usual Dilution: add dose to 50 mL minibag of 0.9% NaCl


IV Continuous Infusion NO

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

  • 0.15  -  0.2 mg/kg/day for 1-7 days (usually no more than 3 days required)
  • Usual maximum dose: 6 mg/dose
Potential hazards of parenteral administration: 
  • Fever, headache, abdominal pain, nausea, vomiting, rash with or without erythema, dyspnea
  • Injection site pain or local reaction
  • Anaphylaxis, bronchospasm
  • Usually indicated for uric acid level greater than 400
  • Contraindicated in patients with G-6PD deficiency (risk of hemolysis)
  • Maintain anaphylaxis precautions and have medications available at the bedside
  • NB: All blood samples for uric acid assay must be immediately placed on ice (heparin/green top tube) and run immediately. Rasburicase's enzymatic activity continues to degrade uric acid levels in blood sample and will give a falsely low reading.  (May wish to pre-cool sample tubes.)

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.